NCT05152472View on ClinicalTrials.gov

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined with Atezolizumab Versus Imatinib Resumption Alone in Patients with Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

PHASE2RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

January 14, 2022

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Unresectable Gastrointestinal Stromal Tumor (GIST)Locally Advanced Gastrointestinal Stromal Tumor (GIST)Metastatic Gastrointestinal Stromal Tumor
Interventions
DRUG

Atezolizumab 1200 mg

(Intravenous administration)

DRUG

Imatinib 400 MG

(Per os)

Trial Locations (12)

13385

RECRUITING

Hôpital de La Timone, Marseille

33076

RECRUITING

Institut Bergonié, Bordeaux

35042

RECRUITING

Centre Eugène Marquis, Rennes

37044

RECRUITING

Chru Tours, Tours

44805

RECRUITING

Institut de cancérologie de l'Ouest, Saint-Herblain

51090

RECRUITING

Hôpital Robert Debré, Reims

59020

RECRUITING

Centre Oscar Lambret, Lille

67200

RECRUITING

ICANS CHRU de Strasbourg, Strasbourg

69373

RECRUITING

Centre Léon Bérard, Lyon

86000

RECRUITING

CHU Poitiers, Poitiers

94805

RECRUITING

Institut Gustave Roussy, Villejuif

06189

RECRUITING

Centre Antoine Lacassagne, Nice

All Listed Sponsors
lead

Centre Leon Berard

OTHER